ME Therapeutics Holding (XCNQ:METX) Cash, Cash Equivalents, Marketable Securities : C$1.35 Mil (As of Feb. 2024)

View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Cash, Cash Equivalents, Marketable Securities?

ME Therapeutics Holding's quarterly cash, cash equivalents, marketable securities declined from Aug. 2023 (C$0.65 Mil) to Nov. 2023 (C$0.38 Mil) but then increased from Nov. 2023 (C$0.38 Mil) to Feb. 2024 (C$1.35 Mil).

ME Therapeutics Holding's annual cash, cash equivalents, marketable securities increased from . 20 (C$0.00 Mil) to Aug. 2022 (C$0.08 Mil) and increased from Aug. 2022 (C$0.08 Mil) to Aug. 2023 (C$0.65 Mil).

ME Therapeutics Holding Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for ME Therapeutics Holding's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Cash, Cash Equivalents, Marketable Securities Chart

ME Therapeutics Holding Annual Data

Trend

Aug22

Aug23

Cash, Cash Equivalents, Marketable Securities

0.08

0.65

ME Therapeutics Holding Quarterly Data
	Aug22	Dec22	May23	Aug23	Nov23	Feb24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			0.74	0.63	0.65	0.38	1.35

ME Therapeutics Holding Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

ME Therapeutics Holding (XCNQ:METX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

ME Therapeutics Holding Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

Q9T:Germany

Address

177 Robson Street, Vancouver, BC, CAN, V6B 0N3

Website

https://www.metherapeutics.com

ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines